Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJae-Hong ParkDNDavid NemirovskyPIPrioty Islam

Discussion

Loading...

Member takes

Overview

Phase II study shows 90% progression-free survival in patients with chronic lymphocytic leukemia, indicating a minimal residual disease-guided treatment approach may be effective.

Key Points

  • 90% progression-free survival achieved at 36 months, highlighting the efficacy of undetectable minimal residual disease in treatment strategies.
  • A total of 100 patients initiated treatment, with 51 participants achieving undetectable minimal residual disease after 9 cycles of therapy.
  • Analysis employed machine learning and RNA sequencing to determine the relationship between patient characteristics and treatment outcomes.
  • Supports using minimal residual disease status to guide treatment duration, warranting further investigation into its long-term efficacy.

Cite This Study

Park et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1b0https://doi.org/10.1182/blood-2025-3902
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  2. 2Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting2025 · 1 citations
  3. 3Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations
  4. 4Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial2025
  5. 5Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma2025 · 5 citations